David A. Siegel Beam Therapeutics Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,700 shares of BEAM stock, worth $284,513. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,700
Previous 42,800
75.0%
Holding current value
$284,513
Previous $1 Million
73.85%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BEAM
# of Institutions
236Shares Held
75.2MCall Options Held
438KPut Options Held
232K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$218 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.84MShares$209 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$203 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.53MShares$174 Million1.52% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$129 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.87B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...